Skip to content Skip to navigation

Lidoderm Generic Antitrust Settlement

Closed Settlement Statement: 
According to court documents, the claim submission deadline has passed. Please contact the claims administrator if you have any questions.
Settlement Structure: 
Case Summary: 

Three settlements resolve class actions against a number of companies:

  • Endo Pharmaceuticals Inc. (“Endo”)
  • Teikoku Pharma USA, Inc., Teikoku Seiyaku Co., Ltd. (together “Teikoku”)
  • Actavis, Inc., Watson Laboratories, Inc., Actavis plc, Anda Inc., Anda Pharmaceuticals, Inc. and Valmed Pharmaceuticals, Inc. (together “Watson”)

The complaint alleged that as part of a 2012 settlement of a patent infringement case, Endo and Teikoku paid Watson to delay introduction of a generic version of Lidoderm. Plaintiffs in the case include both consumers and third-party payors who claim that the anticompetitive agreement between the companies violated antitrust laws and kept prices of Lidoderm artificially high.

Docket Number: 
Endo Pharmaceuticals
Class Period: 
Thursday, August 23, 2012 to Friday, August 1, 2014
Filing Deadline: 
Monday, October 1, 2018
Objection Deadline: 
Tuesday, August 21, 2018
Final Approval Hearing: 
Wednesday, September 12, 2018
Lidoderm Packaging